sign free newsletters benefits aducanumab justify fda approval given small benefit high price pharmaceutical giant biogen admits mistake march stopped pair trials experimental alzheimer drug deep analysis data released thursday suggests drug called aducanumab difference patients took highest dose longest period time studies earlier results muddied discontinuation studies initial data suggested drug failed offer significant benefit unintended differences trials meant identical news conference thursday biogen vice president samantha budd haeberlein explained patients successful trial took highest dose drug longer alzheimer experts accept biogen explanation hope u.s. food drug administration soon approve drug sharon cohen medical director toronto memory program investigator